Financial PerformanceKorlym sales revenue was $163.8M for the quarter, and beat both our estimate and the Street consensus.
Market PotentialPhysicians are increasingly aware that hypercortisolism is much more prevalent than was previously assumed and therefore are screening more patients for the disorder, which ultimately leads to an increase in new scripts of Korlym as more patients are identified.
Product ExpansionThe company is also expanding into other disease areas, including oncology and metabolic disorders, with an ongoing Phase III trial in platinum-resistant ovarian cancer and earlier phase trials in prostate cancer, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH).